CTOs on the Move

Synecor

www.synecor.com

 
Synecor is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.synecor.com
  • 1414 Raleigh Rd Ste 415
    Chapel Hill, NC USA 27517
  • Phone: 919.883.3220

Executives

Name Title Contact Details

Similar Companies

Thrive Health Plans

Thrive Health Plans is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Practical Applications

Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoPrecise Antibodies

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.

Principia Biopharma

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

480 Biomedical

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.